Adjuvant chemotherapy in osteosarcoma: An odyssey of rejection and vindication

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 219-237

  Jaffe, Norman ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ACUTE LEUKEMIA; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LIMB AMPUTATION; LIMB SALVAGE; LUNG METASTASIS; MICROMETASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THORACOTOMY; UNSPECIFIED SIDE EFFECT; VESICULAR RASH; ADJUVANT CHEMOTHERAPY; BONE NEOPLASMS;

BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; OSTEOSARCOMA;

EID: 77953662634     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_11     Document Type: Conference Paper

References (65)

1. Santayana G. The Life of Reason, or The Phases of Human Progress. 2nd ed. New York: Scribner; 1936.
2. Friedman M, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972;45:482-510.
3. Cade S. Osteogenic sarcoma. A study based on 113 patients. J R Coll Surg Edinb. 1955;l:79-111.
4. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in children in acute leukemia produced by folic acid antagonist 4-aminopteroyl-glutanic acid (aminopterin). New Engl J Med. 1946;238:787-793.
5. Golden A, Mantel N, Greenhouse SW, et al. Effect of delayed administration of Citrovorin factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res. 1954;14:43-48.
6. Burchenal JH. Human leukemias. Bibl Hematol. 1975;40:65-77.
7. Djerassi I, Abir E, Boyer GL, et al. Long term remissions in childhood acute leukemia: use of infrequent infusions of methotrexate: supportive roles of platelet transfusions and citrovorum factor. Clin Pediatr. 1966;5:502-509.
8. Zager RF, Frisby SA, Oliverio VT. The effects of antibiotics and cancer chemotherapeutic agents in the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res. 1973;33:1670-1676.
9. Jaffe N. Recent advances in the chemotherapy of osteogenic sarcoma. Cancer. 1972;30:1627-1631.
10. Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate treatment and citrovorum factor in osteogenic sarcoma. New Engl J Med. 1974;291:994-997.
11. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep:. 1964;35:1-28.
12. Laster WR Jr, Mayo JG, Simpson-Herren L, et al. Success and failure in the treatment of solid tumors. II. Kinetic parameters and cell cure of moderately advanced carcinoma. Cancer Chemother Rep. 1969;53:169-188.
13. Schabel FM Jr. Concepts for systemic treatment of micro-metastases. Cancer. 1975;35:15-24.
14. Goorin AM, Delorey M, Gelber RD, et al. Dana-Farber Cancer Institute/The Children's Hospital adjuvant chemotherapy trials for osteosarcoma: three sequential studies. Cancer Treat Symp. 1985;3:155-159.
15. Goorin AM, Perez-Atayde A, Gebhardt M, et al. Weekly high dose methotrexate and doxorubicin for osteosarcoma: The Dana Farber Cancer Institute/The Children's Hospital Study III. J Clin Oncol. 1987;5:1178-1184.
16. Rosen G, Nirenberg A, Caparros B, et al. Osteogenic sarcoma: eight-percent, three-year disease- free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr. 1981;56:213-220.
17. Sutow WW, Gehan EA, Vietti TG, et al. Multidrug chemotherapy in primary osteosarcoma. J Bone Joint Surg Am. 1976;58:629-633.
18. Pratt C, Shanks E, Hustu O, et al. Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity. Cancer. 1979;39:51-57.
19. Muggia FM, Louie AC. Five years of adjuvant chemotherapy: more questions than answers. Cancer Treat Rep. 1978;62:30-36.
20. Rab CT, Ivins JC, Childs RE, et al. Elective whole lung irradiation in the treatment of osteogenic sarcoma. Cancer. 1976;38:939-942.
21. Taylor WF, Ivins JG, Dahlin D, et al. Osteogenic sarcoma experience at the Mayo Clinic, 1963-1974. In: Terry WD, Windhorst D, eds. Immunotherapy of Cancer. Present Status of Trials in Man, Progress in Cancer Research and Therapy, vol.VI. New York: Raven Press; 1978:257-269.
22. Taylor WF, Ivins JC, Prichard DJ, et al. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc. 1985;60(2):91-104.
23. Frei E III, Blum R, Jaffe N. Sarcoma: natural history and treatment. In: Terry WD, Windhorst D, eds. Immunotherapy of Cancer. Present Status of Trials in Man, Progress in Cancer Research and Therapy, vol.VI. New York: Raven Press; 1978:248-255.
24. Gehan EA, Sutow WW, Urube Botero T, et al. Osteosarcoma. The MD Anderson experience 1850-1974. In: Terry WD, Windhorst D, eds. Immunotherapy of Cancer. Present Status of Trials in Man, Progress in Cancer Research and Therapy, vol.VI. New York: Raven Press; 1978:271-282.
25. Miké V, Marcove RC. Osteogenic sarcoma under the age of 21. Experiences at Memorial Sloan Kettering Cancer Center. In: Terry WD, Windhorst D, eds. Immunotherapy of Cancer. Present Status of Trials in Man, Progress in Cancer Research and Therapy, vol.VI. New York: Raven Press; 1978:282-293.
26. Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma in childhood. NY State J Med. 1971;71:855-859.
27. Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty years' experience at the Instituto Ortopedico Rizzoli. Cancer. 1981;48:1569-1581.
28. Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose versus Adriamycinmethotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol. 1986;22:1337-1345.
29. Bacci G, Picci P, Calderoni P, et al. Full lung tomograms and bone scanning in the initial workup of patients with osteogenic sarcoma. A review of 126 cases. Eur J Cancer Clin Oncol. 1982;18:967-971.
30. Muhm JR, Prichard DJ. Computed tomography for detection of pulmonary metastases in patients with osteogenic sarcoma. Proc Am Assoc Cancer Res. 1980;21:593.
31. Cohen M, Provisor A, Smith WL, et al. Efficacy of whole lung tomography on diagnosing metastases from solid tumors in children. Radiology. 1981;141:375-378.
32. Gordon RE, Mettler FA Jr, Wicks J, et al. Chest x-rays and full lung tomograms in gynecologic malignancy. Cancer. 1983;52:559-562.
33. Wilimas J, Hammon E, Champion J, et al. The value of computerized tomography (CT) as a routine follow-up procedure for patients with Wilms tumor. Am Soc Clin Oncol. 1983;2:80 (Abstr 34).
34. Jaffe N, Farber S, Traggis D, et al. Favorable response of metastatic osteogenic sarcoma to pulse high dose methotrexate with citrovorin rescue and radiation therapy. Cancer. 1973;31:1367-1373.
35. Jaffe N, Watts H, Fellows K, et al. Local en bloc resection for limb preservation. Cancer Treat Rep. 1978;62:217-223.
36. Jaffe N, Frei E III, Traggis D, et al. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977;39:45-50.
37. Frei E, Jaffe N, Gero M, et al. Guest editorial. Adjuvant chemotherapy of osteogenic sarcoma: progress and perspectives. J Natl Cancer Inst. 1978; 60:3-10.
38. Jaffe N, Frei E III, Watts H, et al. High dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat Rep. 1978;62:259-264.
39. Jaffe N. Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors. Cancer Chemother Rep. 1974;58:275-280.
40. Jaffe N, Traggis D. Toxicity of high-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) in osteogenic sarcoma. Cancer Chemother Rep. 1975;6:31-36.
41. Pitman SW, Parker M, Tattersall MH, et al. Clinical trial of high-dose methotrexate (NSC- 740) with citrovorum factor (NSC-3590) - toxicologic and therapeutic observations. Cancer Chemother Rep. 1975;6:43-49.
42. Jaffe N, Frei E III, Traggis D, et al. High-dose methotrexate with citrovorum factor in osteogenic sarcoma. Progress report II. Cancer Treat Rep. 1977;61:675-679.
43. Jaffe N, Traggis D, Cassady JR, et al. Multidisciplinary treatment for macrometastatic osteogenic sarcoma. Br Med J. 1976;2:1039-1041.
44. Jaffe N, Link M, Traggis D, et al. The role of high dose methotrexate in osteogenic sarcoma. Sarcomas of soft tissue and bone in childhood. Natl Cancer Inst Monogr. 1981;56:201-206.
45. Edmonson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol. 1984;2:152-156.
46. Carter SK. Adjuvant chemotherapy in osteogenic sarcoma.The triumph that isn't? J Clin Oncol. 1984;2:147-148.
47. Jaffe N. Adjuvant chemotherapy in osteogenic sarcoma. J Clin Oncol. 1984;2:1179-1181.
48. Carter SK. Reply: adjuvant chemotherapy in osteosarcoma. J Clin Oncol. 1984;2:1181.
49. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604-1608.
50. Goorin AM, Frei E III, Abelson HT. Adjuvant chemotherapy for osteosarcoma: a decade of experience. Surg Clin North Am. 1981;61:1379-1389.
51. Kolate GB. Dilemma in cancer treatment. Science. 1980;209:792-794.
52. Brostrom LA, Apairsi T, Ingimarsson SN, et al. Can historical controls be used in current clinical trials in osteosarcoma? Metastasis and survival in a historical and concurrent group. Int J Radiat Oncol Biol Phys. 1980;6:1717-1721.
53. Lang EB, Levin AS. Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma? Cancer Treat Rep. 1982;66:1699-1704.
54. Jaffe N, van Eys J, Gehan E. Response to: "Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma?". Cancer Treat Rep. 1983;67:743-744.
55. Cox DR. Regression models and life tables (with discussion). J R Stat B. 1972;187-220.
56. Jaffe N, Smith E, Abelson HT, et al. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol. 1983;1:251-254.
57. Jaffe N, Traggis D, Cohen DG. The impact of high dose methotrexate in the management of osteogenic sarcoma. In: Proceedings of the Twelfth International Cancer Congress, vol.10. Oxford: Pergamon Press; 1979:175-179.
58. Link MP, Vietti TJ. Reply: Role of adjuvant chemotherapy in the treatment of osteosarcoma. Cancer Treat Rep. 1983;67:744-745.
59. D'Angio GJ, Evans AE. Bone tumors - a commentary. In: D'Angio GJ, Evans AE, eds. Bone Tumours and Soft-Tissue Sarcomas, Progress in Cancer Research and Therapy, vol.VI. Baltimore, MD: Edward Arnold; 1985:121-124.
60. Rosen G, Murphy ML, Huvos AG, et al. Chemotherapy en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37:1-11.
61. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55-67.
62. Link MP, Goorin AM, Miser A, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. New Engl J Med. 1986;314:1600-1606.
63. Eilber FR, Dauglass HI Jr, Mendel ER, et al. Adjuvant Adriamycin and cisplatin in newlydiagnosed nonmetastatic osteosarcoma of the extremity. J Clin Oncol. 1986;4:353-362.
64. Holland JF. Adjuvant chemotherapy of osteosarcoma: no runs, no hits, two men left on base. J Clin Oncol. 1987;5:4-6.
65. Winkler K, Bielack S. Chemotherapy for osteosarcoma. Semin Orthop. 1988;3:48-58..